Literature DB >> 30312589

Implications of the Revised Common Rule for Human Participant Research.

Evan G DeRenzo1, Joel Moss2, Eric A Singer3.   

Abstract

This paper looks at the implications of changes to the regulatory governance of human participant research that can be expected with implementation of the Revised Common Rule (RCR). The RCR refers to revisions of the existing federal regulations that govern the performance of research involving human subjects (ie, clinical research) in the United States and, under certain circumstances, when such research is also performed outside the United States. The term "common" is included because it refers to the fact that these regulations, often referred to as Code of Federal Regulations 46, is the common denominator regulations agreed to across a wide swath of federal agencies.
Copyright © 2018 American College of Chest Physicians. All rights reserved.

Entities:  

Keywords:  biospecimen; capacity; clinical research; common rule; human participant research; human subject research; informed consent; institutional review board; research ethics; revised common rule

Mesh:

Year:  2018        PMID: 30312589      PMCID: PMC6363814          DOI: 10.1016/j.chest.2018.09.022

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  Alternatives to local institutional review board (IRB) system debated.

Authors:  Dennis M Maloney
Journal:  Hum Res Rep       Date:  2006-04

2.  Regulating Research with Biospecimens under the Revised Common Rule.

Authors:  Holly Fernandez Lynch; Michelle N Meyer
Journal:  Hastings Cent Rep       Date:  2017-05       Impact factor: 2.683

Review 3.  Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature.

Authors:  Devon K Check; Kevin P Weinfurt; Carrie B Dombeck; Judith M Kramer; Kathryn E Flynn
Journal:  Clin Trials       Date:  2013-05-10       Impact factor: 2.486

4.  Parent ratings of ability to consent for clinical trials in fragile X syndrome.

Authors:  Donald B Bailey; Melissa Raspa; Anne Wheeler; Anne Edwards; Ellen Bishop; Carla Bann; David Borasky; Paul S Appelbaum
Journal:  J Empir Res Hum Res Ethics       Date:  2014-07       Impact factor: 1.742

5.  Public's approach to surrogate consent for dementia research: cautious pragmatism.

Authors:  Raymond De Vries; Kerry A Ryan; Aimee Stanczyk; Paul S Appelbaum; Laura Damschroder; David S Knopman; Scott Y H Kim
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-12       Impact factor: 4.105

6.  Models of consent to return of incidental findings in genomic research.

Authors:  Paul S Appelbaum; Erik Parens; Cameron R Waldman; Robert Klitzman; Abby Fyer; Josue Martinez; W Nicholson Price; Wendy K Chung
Journal:  Hastings Cent Rep       Date:  2014-06-11       Impact factor: 2.683

7.  Local IRBs vs. federal agencies: shifting dynamics, systems, and relationships.

Authors:  Robert L Klitzman
Journal:  J Empir Res Hum Res Ethics       Date:  2012-07       Impact factor: 1.742

8.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  2013-11-27       Impact factor: 56.272

9.  How local IRBs view central IRBs in the US.

Authors:  Robert Klitzman
Journal:  BMC Med Ethics       Date:  2011-06-23       Impact factor: 2.652

10.  Researchers' views on informed consent for return of secondary results in genomic research.

Authors:  Paul S Appelbaum; Abby Fyer; Robert L Klitzman; Josue Martinez; Erik Parens; Yuan Zhang; Wendy K Chung
Journal:  Genet Med       Date:  2014-12-11       Impact factor: 8.822

View more
  1 in total

1.  Leveraging Interdisciplinary Teams to Develop and Implement Secure Websites for Behavioral Research: Applied Tutorial.

Authors:  Christie L Martin; Eydie N Kramer-Kostecka; Jennifer A Linde; Sarah Friend; Vanessa R Zuroski; Jayne A Fulkerson
Journal:  J Med Internet Res       Date:  2020-09-23       Impact factor: 5.428

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.